

Global Diabetic Nephropathy Drugs and Companies Pipeline Review H2 2016

Diabetic Nephropathy Treatment Pipeline Review H2 2016

PUNE, INDIA, September 12, 2016
/EINPresswire.com/ -- Summary

'[Diabetic Nephropathy](#) - Pipeline Review, H2 2016', provides an overview of the Diabetic Nephropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Nephropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects.



Complete report details @

<https://www.wiseguyreports.com/reports/636759-diabetic-nephropathy-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ <https://www.wiseguyreports.com/sample-request/636759-diabetic-nephropathy-pipeline-review-h2-2016>

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy

- The report reviews pipeline therapeutics for Diabetic Nephropathy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Diabetic Nephropathy therapeutics and enlists all their major and minor projects
- The report assesses Diabetic Nephropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Diabetic Nephropathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ <https://www.wiseguyreports.com/enquiry/636759-diabetic-nephropathy-pipeline-review-h2-2016>

Key points in table of content

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Diabetic Nephropathy Overview 9

Therapeutics Development 10

Pipeline Products for Diabetic Nephropathy - Overview 10

Pipeline Products for Diabetic Nephropathy - Comparative Analysis 11

Diabetic Nephropathy - Therapeutics under Development by Companies 12

Diabetic Nephropathy - Therapeutics under Investigation by Universities/Institutes 15

Diabetic Nephropathy - Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Diabetic Nephropathy - Products under Development by Companies 20
Diabetic Nephropathy - Products under Investigation by Universities/Institutes 23
Diabetic Nephropathy - Companies Involved in Therapeutics Development 24
AbbVie Inc 24
Ampio Pharmaceuticals, Inc. 25
Antisense Therapeutics Limited 26
Araim Pharmaceuticals, Inc. 27
Arena Pharmaceuticals, Inc. 28
Astellas Pharma Inc. 29
AstraZeneca Plc 30
Bayer AG 31
BiOrion Technologies B.V. 32
Boehringer Ingelheim GmbH 33
Cellmid Limited 34
ChemoCentryx, Inc. 35
CSL Limited 36
Daiichi Sankyo Company, Limited 37
Dimerix Bioscience Pty Ltd 38
Dong Wha Pharma Co., Ltd. 39
Dynamis Therapeutics, Inc. 40
Eli Lilly and Company 41
Galectin Therapeutics, Inc. 42
GenKyoTex S.A. 43
Gilead Sciences, Inc. 44
GlaxoSmithKline Plc 45
Glucox Biotech AB 46
GNI Group Ltd. 47
Islet Sciences, Inc. 48
Jenrin Discovery, Inc. 49
Johnson & Johnson 50
Mallinckrodt Plc 51
Mesoblast Limited 52
Mitsubishi Tanabe Pharma Corporation 53
MorphoSys AG 54
Noxxon Pharma AG 55
Omeros Corporation 56
Otsuka Holdings Co., Ltd. 57
PhytoHealth Corporation 58
ProMetic Life Sciences Inc. 59
Serodus ASA 60
Takeda Pharmaceutical Company Limited 61
Theravance Biopharma, Inc. 62
Tobira Therapeutics, Inc. 63
Vascular Pharmaceuticals, Inc. 64
Vicore Pharma AB 65
Diabetic Nephropathy - Therapeutics Assessment 66
Assessment by Monotherapy Products 66
Assessment by Target 67
Assessment by Mechanism of Action 70
Assessment by Route of Administration 74
Assessment by Molecule Type 76
Drug Profiles 78

11-RVIVIT - Drug Profile 78
A-717 - Drug Profile 79
Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and
Oncology - Drug Profile 80
APD-371 - Drug Profile 81
APX-115 - Drug Profile 82
ASP-8232 - Drug Profile 83
ATL-1103 - Drug Profile 84
atrasentan hydrochloride - Drug Profile 91
baricitinib - Drug Profile 93
BI-703704 - Drug Profile 100
BOT-191 - Drug Profile 101
C-21 - Drug Profile 102
canagliflozin - Drug Profile 104
CCX-140 - Drug Profile 111
cenicriviroc mesylate - Drug Profile 115
cibinetide - Drug Profile 122
corticotropin - Drug Profile 125
CS-3150 - Drug Profile 127
CSL-346 - Drug Profile 129
Cyndacel-M - Drug Profile 130

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=636759

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.
© 1995-2018 IPD Group, Inc. All Right Reserved.